FDA Reexamines Opioid Policies

The agency said last week it will re-evaluate its risk-benefit framework for the drugs, with an eye on public health effects. Read More

Stryker to Acquire Synergetics USA’s Neuro Portfolio

Deal expected to close in the first quarter. Read More
The Solutions Center